Nuvation Bio Management
Management Kriterienprüfungen 2/4
Nuvation Bio CEO ist David Hung , ernannt in Apr 2018, hat eine Amtszeit von 8.08 Jahren. Die jährliche Gesamtvergütung beträgt $3.88M , bestehend aus 16.8% Gehalt und 83.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 17.31% der Aktien des Unternehmens, im Wert von $284.53M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.8 Jahre bzw. 2.9 Jahre.
Wichtige Informationen
David Hung
Geschäftsführender
US$3.9m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 16.77% |
| Amtszeit als Geschäftsführer | 8.1yrs |
| Eigentum des Geschäftsführers | 17.3% |
| Durchschnittliche Amtszeit des Managements | 3.8yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 2.9yrs |
Jüngste Management Updates
Recent updates
Analyseartikel • May 08
Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit
Investors in Nuvation Bio Inc. ( NYSE:NUVB ) had a good week, as its shares rose 8.1% to close at US$4.81 following the...
Neues Narrativ • Mar 04
Nuvation Bio Inc. (NUVB): Transitioning from Biotech Pipeline to Commercial Contender in 2026.
Nuvation Bio (NUVB) is navigating a high-stakes transition into a commercial-stage oncology firm, with its stock trading at $4.74 as of the March 4, 2026, afternoon session. The shares saw a notable 8.60% recovery today, partially reclaiming ground after a staggering 25.34% drop on March 3rd following its latest financial disclosures.Seeking Alpha • Feb 20
Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade)
Summary Nuvation Bio is upgraded from Sell to Hold, reflecting improved IBTROZI adoption but growing competitive risks. IBTROZI's rapid uptake in ROS1+ NSCLC establishes a valuation floor, but Nuvalent's zidesamtinib could erode its market share by 2027. Safusidenib's shift to high-grade gliomas avoids direct competition but limits total addressable market and near-term valuation impact. Current valuation appears modestly overvalued at $4–$5/share, with pipeline attrition and competitive threats tempering long-term enthusiasm. Read the full article on Seeking AlphaAnalyseartikel • May 17
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Feb 13
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Summary Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism. Concerns include reliance on Chinese study data and competition from established pharma giants, but Nuvation's cash reserves suggest readiness for a wide-scale launch. Ahead of the PDUFA date, Nuvation presents a speculative investment opportunity, given it is potentially undervalued with a "blockbuster-in-waiting" drug candidate so close to approval, and further promising pipeline assets. Read the full article on Seeking AlphaAnalyseartikel • Nov 20
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Oct 21
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Summary Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, Taletrectinib's potential $1bn market opportunity and strong financials make NUVB a compelling investment ahead of its PDUFA. Risks include a competitive landscape with established drugs and emerging rivals like NVL-520, which could impact market share. With solid leadership and a strong cash position, NUVB is well-positioned for growth, making it a stock to watch closely. Read the full article on Seeking AlphaSeeking Alpha • Aug 08
Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Summary Nuvation Bio transitioned from early-stage to late-stage biotech with a near-approval, sitting at a $700 million market cap. The main project is taletrectinib, a novel ROS1 inhibitor with high response rates observed in studies, aiming for NDA filing. Financially stable with cash runway of 12-13 quarters, potential for accelerated approval of taletrectinib, but uncertainty in market adoption. Read the full article on Seeking AlphaAnalyseartikel • Aug 07
Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 20
Nuvation Bio: A Potentially Transformative Acquisition
Summary Nuvation Bio stock has been on a roll since late October, as the shares have roughly tripled since then. The main driver of this rally is the potentially transformative acquisition of AnHeart Therapeutics. This greatly enhanced Nuvation's pipeline and prospects. Analyst firms have a universally positive outlook on the company and its equity as well. In addition, Nuvation is well-funded, with the majority of the stock's market cap represented in cash and marketable securities on the company's balance sheet. An analysis around Nuvation Bio follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Mar 31
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Summary Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
Nuvation: Cash Is King, Science Is An Afterthought
Summary Nuvation Bio is developing BET inhibitors for solid tumors, with lead asset NUV-868 in phase 1/1b trials. BET proteins play a role in gene regulation and chromatin remodeling, and inhibiting them may be therapeutic for cancer. NUV-868 is highly selective for BD2, potentially reducing toxicity compared to other BET inhibitors. Read the full article on Seeking AlphaAnalyseartikel • Sep 14
We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Feb 14
Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Baupost Group took new stakes in Altice USA (NYSE:ATUS), with a 3.88M shares, and in Herbalife Nutrition (NYSE:HLF), with 2.00M shares, during the quarter ended Dec. 31, 2022, according to its latest 13F filing. Overall, the firm run by Seth Klarman increased its bets on tech companies and reduced its exposure to health-related stocks. The hedge fund run by Seth Klarman exited stakes in Dropbox (NASDAQ:DBX), Encompass Health (NYSE:EHC), and Enhabit (NYSE:EHAB). The firm increased stakes in Fidelity National Information Services (NYSE:FIS) to 2.16M shares from 615K in the prior quarter; in Meta Platforms (NASDAQ:META) to 1.73M shares from ~689K shares; Google parent Alphabet (NASDAQ:GOOG) to 3.99M shares from ~1.38M shares; and Amazon (NASDAQ:AMZN) to 990K shares from 248K. Reduced its stakes in Nuvation Bio (NYSE:NUVB) to ~4.81M shares from 10.4M shares, (NASDAQ:FISV), in Qorvo (NASDAQ:QRVO) to 5.73M shares from ~6.78M, and in Theravance Biopharma (NASDAQ:TBPH) to 11.4M shares from 13.4M, according to the filing. Earlier in February, Klarman blamed the Fed's response to the 2008 financial crisis for the markets' volatility in 2022Analyseartikel • Feb 10
We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Nov 09
We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Nov 03
Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nuvation Bio press release (NYSE:NUVB): Q3 GAAP EPS of -$0.12 beats by $0.02. Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $673.9M as of September 30, 2022.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$146m |
| Dec 31 2025 | US$4m | US$650k | -US$205m |
| Sep 30 2025 | n/a | n/a | -US$217m |
| Jun 30 2025 | n/a | n/a | -US$203m |
| Mar 31 2025 | n/a | n/a | -US$606m |
| Dec 31 2024 | US$4m | US$610k | -US$568m |
| Sep 30 2024 | n/a | n/a | -US$532m |
| Jun 30 2024 | n/a | n/a | -US$511m |
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$4m | US$593k | -US$76m |
| Sep 30 2023 | n/a | n/a | -US$83m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$105m |
| Dec 31 2022 | US$8m | US$570k | -US$104m |
| Sep 30 2022 | n/a | n/a | -US$108m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$88m |
| Dec 31 2021 | US$5m | US$550k | -US$87m |
| Sep 30 2021 | n/a | n/a | -US$75m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$1m | US$475k | -US$42m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$33m |
| Dec 31 2019 | US$364k | US$218k | -US$34m |
Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD3.88M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.47M).
Entschädigung vs. Einkommen: DavidDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
David Hung (67 yo)
8.1yrs
Amtszeit
US$3,876,736
Vergütung
Dr. David T. Hung, M.D., serves as Founder, President, Chief Executive Officer and Director at Nuvation Bio Inc since April 2018 and has been it's Chairman of the Board since September 03, 2024. He founded...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 8.1yrs | US$3.88m | 17.31% $ 284.5m | |
| CFO & Principal Financial Officer | 1.6yrs | US$1.48m | 0.0036% $ 59.8k | |
| Chief Scientific Officer | 6.9yrs | US$1.47m | keine Daten | |
| VP of Finance and Principal Accounting & Financial Officer | 2.5yrs | keine Daten | 0.0050% $ 82.0k | |
| Chief Technical Operations Officer | no data | US$3.31m | 0.0069% $ 113.2k | |
| Vice President of Corporate Development & Investor Relations | no data | keine Daten | keine Daten | |
| Chief Legal Officer & Corporate Secretary | no data | keine Daten | keine Daten | |
| Chief People Officer | 6.6yrs | keine Daten | 0.0094% $ 153.8k | |
| Chief Regulatory Officer | 3.8yrs | keine Daten | 0.015% $ 250.1k | |
| Chief Medical Officer | 3.8yrs | US$1.34m | keine Daten | |
| Chief Commercial Officer | 2.1yrs | US$2.28m | 0.024% $ 396.4k |
3.8yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: NUVBDas Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 8.1yrs | US$3.88m | 17.31% $ 284.5m | |
| Independent Director | 5.6yrs | US$445.00k | 0.072% $ 1.2m | |
| Independent Director | 6.8yrs | US$436.25k | 0.049% $ 812.7k | |
| Lead Independent Director | 5.8yrs | US$483.00k | 0.0014% $ 23.7k | |
| Independent Director | 2.3yrs | US$422.50k | 0.057% $ 944.0k | |
| Member of Scientific Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Independent Director | 6.9yrs | US$446.00k | 0.087% $ 1.4m | |
| Member of Scientific Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 2.9yrs | keine Daten | keine Daten |
2.9yrs
Durchschnittliche Betriebszugehörigkeit
64.5yo
Durchschnittliches Alter
Erfahrener Vorstand: NUVBDie Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 02:12 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Nuvation Bio Inc. wird von 14 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |